Adaptive Biotechnologies (ADPT) Q4 2025: MRD Revenue Jumps 46% as ASP and Volume Tailwinds Strengthen
Adaptive Biotechnologies closed 2025 with a step-function leap in MRD growth, margin expansion, and disciplined spending, setting a new baseline for profitability and scale. The company’s durable execution across clinical testing, pharma partnerships, and immune medicine data licensing signals a multi-year runway for both revenue and operating leverage. Management’s 2026 guidance leans on further volume gains, payer wins, and operational efficiency, but execution risk remains around ASP realization and competitive dynamics.
Summary
- MRD Growth Engine: Broad-based clinical and pharma adoption, with higher ASP and blood-based testing, drives outsized expansion.
- Margin Inflection: Operational leverage and NovaSeq X Plus transition fuel sequencing gross margin gains, with further upside targeted.
- Immune Medicine Monetization: Pfizer data deals validate data asset, but discipline on spend and focus on scalable partnerships guide strategy.
Business Overview
Adaptive Biotechnologies develops and commercializes next-generation sequencing-based diagnostics and immune medicine data solutions. Its core business is MRD (Minimal Residual Disease) testing, primarily through its ClonoSeq assay, which monitors blood cancers via highly sensitive detection of residual disease. The company also operates an immune medicine segment, leveraging its proprietary TCR (T-cell receptor) antigen data for pharmaceutical partnerships and target discovery. Revenue is split between clinical diagnostics, pharma services, and data licensing, with MRD representing the vast majority of sales and profit contribution.
Performance Analysis
Top-line momentum in 2025 was driven by a 46% increase in MRD revenue, underpinned by a 43% rise in ClonoSeq test volumes and a 17% increase in average selling price (ASP) per test. Clinical testing led the charge, with multiple myeloma, ALL, CLL, DLBCL, and MCL all contributing to growth. Blood-based testing, which is less invasive and more scalable than bone marrow sampling, now accounts for 47% of ClonoSeq tests and is gaining share, particularly in multiple myeloma.
Pharma MRD revenue grew 20% (11% ex-milestones), supported by a robust $210 million backlog and rising use of MRD as a regulatory endpoint in trials. Immune medicine revenue increased on the back of Pfizer data licensing, though segment profitability remains in investment mode. Sequencing gross margin expanded 12 points to 71% in Q4, reflecting scale, production efficiency, and the NovaSeq X Plus platform transition. Operating expenses were tightly managed, up just 4% in Q4, with the company reducing annual cash burn by 68% and ending the year with $227 million in cash.
- Volume Expansion Across Indications: ClonoSeq test growth was broad-based, with multiple myeloma representing 44% of US volume and strong gains in DLBCL, MCL, and CLL.
- ASP Tailwind from Payer Contracts: Renegotiation with major commercial payers and expanded coverage in DLBCL and CLL drove realized ASP higher and improved cash collections by 74% YoY.
- Margin Leverage from NovaSeq X Plus: Lower cost per sample, labor leverage, and increased throughput contributed to a 5-point sequential and 12-point YoY gross margin gain in Q4.
MRD now contributes 86% of revenue, with clinical and pharma segments at 67% and 33% of MRD revenue, respectively. The company enters 2026 with positive adjusted EBITDA in MRD and a clear path to company-wide profitability.
Executive Commentary
"We believe these priorities position MRD as a scalable, durable, and increasingly profitable growth engine for Adaptive in 2026 and beyond."
Chad Robbins, Chief Executive Officer & Co-Founder
"We expect to achieve positive adjusted EBITDA and positive free cash flow for the whole company by the end of 2026."
Kyle Tesco, Chief Financial Officer
Strategic Positioning
1. MRD Clinical Penetration and Blood-Based Testing
Blood-based testing is becoming the preferred modality, now comprising nearly half of ClonoSeq volume, with management targeting over 50% in 2026. Community setting penetration is also accelerating, now at 33% of test volume, with a goal to exceed 35% this year. EMR integrations (notably with Flatiron and Epic) are driving ordering consistency and serial testing pull-through, with 173 accounts now integrated and 40 more targeted in 2026.
2. ASP and Payer Leverage
ASP expansion is a core lever, supported by successful renegotiation of eight major payer contracts and new coverage wins. The company is targeting an average ASP of $1,400 per test in 2026, up from $1,307 in 2025, with upside potential tied to two large pending contracts. Revenue cycle management improvements and AI-enabled workflows have materially improved cash realization rates.
3. Pharma MRD as a Regulatory Standard
MRD is increasingly embedded as a primary endpoint in interventional trials, with 60% of the pharma portfolio now using MRD endpoints, up from 40% last year. Registrational trials bring higher economic value and a halo effect to clinical adoption. Backlog growth and guideline inclusion in CLL and ALL further cement MRD’s role in drug development and clinical decision-making.
4. Immune Medicine Data Monetization
Pfizer data licensing deals validate Adaptive’s proprietary TCR antigen database, with monetization now focused on AI/ML modeling partnerships and target discovery. The company is deliberately limiting spend, with a 2026 net cash burn target of $15–20 million, and aims to secure additional data partnerships as the market matures.
5. Operational Discipline and Margin Expansion
Sequencing margin expansion is structural, as NovaSeq X Plus adoption and higher volumes drive sustained cost-per-sample reduction. Management sees a path to 75%+ gross margin over the next several years, with further ASP gains and operational leverage supporting operating margin improvement.
Key Considerations
Adaptive’s 2025 results reflect a business pivoting from high-growth to scalable profitability, with several levers in place for continued expansion but also new execution demands as the base grows.
Key Considerations:
- Blood-Based Testing Adoption: Physician preference for minimally invasive blood testing is accelerating, with upside if DLBCL and MCL adoption outpaces guidance.
- ASP Realization and Payer Mix: Execution on two large commercial payer contracts is pivotal for hitting ASP targets, with timing and rate risk flagged by management.
- Pharma Backlog and Regulatory Momentum: Embedding MRD as a trial endpoint increases backlog visibility and pharma revenue quality, but milestone timing remains variable.
- Immune Medicine Commercialization: Pfizer deals are proof points, but broader pharma adoption and scalable data monetization are still in early innings.
- Margin Upside from NovaSeq X Plus: Further efficiency gains are expected as sample volume per run increases, supporting gross margin expansion above 70%.
Risks
Execution risk remains around ASP realization, especially as payer negotiations are still underway and commercial coverage for new indications is not fully locked in. Competitive pressure is rising, with new entrants like Quest introducing lower-cost, lower-sensitivity flow cytometry assays that could pressure price or share at the margin. Pharma revenue is milestone and backlog dependent, with regulatory timelines and trial design shifts introducing variability. Immune medicine monetization is still nascent and requires ongoing investment discipline.
Forward Outlook
For Q1 2026, Adaptive expects:
- Continued sequential growth in ClonoSeq test volume, despite typical Q1 seasonality and weather-related disruptions.
- Stable to rising ASP as payer contracts are implemented through the year.
For full-year 2026, management guided:
- MRD revenue of $255–265 million, implying 22% YoY growth (30% ex-milestones).
- Operating expenses of $350–360 million, up 6% YoY at midpoint.
- Positive adjusted EBITDA and free cash flow for the company by year-end 2026.
Management highlighted several factors that will drive the outlook:
- Volume growth from blood-based testing and community penetration.
- ASP expansion from payer wins and improved revenue cycle management.
- Pharma backlog conversion and new trial endpoints.
Takeaways
Adaptive Biotechnologies’ 2025 performance confirms MRD’s transition from a high-growth niche to a scalable, profitable core business. The company’s disciplined investment in immune medicine data partnerships and operational efficiency provides a foundation for multi-year expansion, though payer dynamics and competition will require vigilant execution.
- MRD Scale and Profitability: Volume, ASP, and margin expansion have reset the baseline for MRD as a durable growth and profit engine, with further leverage expected in 2026.
- Data Monetization Emerges: Pfizer partnerships validate the immune medicine platform, but broader adoption and recurring data revenue will be key watchpoints.
- Execution on Payer and Pharma Levers: Success in commercial payer negotiations and pharma endpoint adoption will determine whether Adaptive can outperform its 2026 guide.
Conclusion
Adaptive Biotechnologies enters 2026 with clear momentum, a proven playbook in MRD, and new validation for its immune medicine data asset. Sustained growth now depends on payer execution, pharma trial integration, and operational discipline, all of which management has prioritized. Investors should watch for ASP realization and competitive response as the next phase unfolds.
Industry Read-Through
Adaptive’s MRD growth trajectory underscores the mainstreaming of molecular minimal residual disease monitoring in hematologic oncology, with blood-based testing and EMR integration becoming table stakes for diagnostics players. The company’s success in driving payer ASP and embedding MRD as a pharma trial endpoint signals a broader shift toward value-based diagnostics and regulatory integration across the sector. Data monetization in immune medicine remains early, but Adaptive’s Pfizer deals highlight the growing appetite for proprietary, large-scale immune receptor datasets to power AI-driven drug discovery. Competitors will need to demonstrate both sensitivity and scalability to keep pace, while pharma partners increasingly demand integrated, validated endpoints in development programs.